Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLNYSE:LEAFCVE:RXCVE:VM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.52+9.1%$1.25$0.77▼$2.63$114.88M1.04308,989 shs368,415 shsLEAFLeaf Group$8.49$8.47$2.48▼$9.50$305.91M2.13959,348 shsN/ARXBioSyentC$11.75+0.4%C$11.49C$9.20▼C$12.13C$134.39M0.934,381 shs400 shsVMVoyageur PharmaceuticalsC$0.31-1.6%C$0.20C$0.04▼C$0.36C$46.21M0.32196,683 shs432,743 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+9.06%+3.13%+15.73%+87.16%-21.04%LEAFLeaf Group0.00%0.00%0.00%0.00%0.00%RXBioSyent+0.43%+0.95%+1.03%+18.69%+17.50%VMVoyageur Pharmaceuticals-1.61%+10.91%+64.86%+64.86%+408.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.0824 of 5 stars3.73.00.00.01.10.00.6LEAFLeaf GroupN/AN/AN/AN/AN/AN/AN/AN/ARXBioSyentN/AN/AN/AN/AN/AN/AN/AN/AVMVoyageur PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00427.70% UpsideLEAFLeaf Group 0.00N/AN/AN/ARXBioSyent 0.00N/AN/AN/AVMVoyageur Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VM, LEAF, CRDL, and RX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/ALEAFLeaf Group$212.06M1.44$0.02 per share400.34$2.19 per share3.88RXBioSyentC$34.06M3.95C$3.82 per share3.07C$3.22 per share3.65VMVoyageur PharmaceuticalsN/AN/AC$0.01 per share35.00C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)LEAFLeaf Group-$8.86MN/AN/A∞N/A-1.94%-7.40%-3.79%N/ARXBioSyentC$7.02MC$0.6219.07∞N/A20.60%20.01%12.86%N/AVMVoyageur Pharmaceuticals-C$1.66M-C$0.01N/A∞N/AN/A-117.77%-30.77%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ALEAFLeaf GroupN/AN/AN/AN/AN/ARXBioSyentC$0.181.53%N/A29.21%N/AVMVoyageur PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26LEAFLeaf Group0.011.651.65RXBioSyent2.903.926.91VMVoyageur Pharmaceuticals4.230.100.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%LEAFLeaf Group70.80%RXBioSyent1.37%VMVoyageur PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%LEAFLeaf Group11.40%RXBioSyent33.65%VMVoyageur Pharmaceuticals10.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableLEAFLeaf Group36036.03 millionN/AOptionableRXBioSyentN/A11.44 millionN/ANot OptionableVMVoyageur PharmaceuticalsN/A151.52 millionN/ANot OptionableVM, LEAF, CRDL, and RX HeadlinesRecent News About These CompaniesVoyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 SharesJuly 1 at 5:07 AM | insidertrades.comVoyageur Pharmaceuticals (CVE:VM) Trading 21.8% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 20% - Here's What HappenedJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 21.8% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 23.6% - Time to Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 20% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Trading 12.7% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast AgentsJune 4, 2025 | msn.comVoyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study ResultsApril 24, 2025 | finance.yahoo.comVoyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market LaunchApril 1, 2025 | finance.yahoo.comVoyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced AgreementMarch 3, 2025 | finanznachrichten.deVoyageur Advances MRI Drug Development Using Next Generation Endohedral FullerenesFebruary 18, 2025 | finance.yahoo.comVoyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025February 6, 2025 | msn.comVoyageur Receives $600K Grant From Alberta Innovates for Product DevelopmentFebruary 6, 2025 | finance.yahoo.comVoyageur Secures $687k of Additional Capital From Warrant ExercisesJanuary 24, 2025 | finance.yahoo.comVoyageur Pharmaceuticals is going global: Why it's time to buy the stockJanuary 23, 2025 | msn.comCanadian Investment Regulatory Organization Trading Halt - VMDecember 21, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - VMDecember 21, 2024 | finance.yahoo.comOne of the best Venture pharma stocks has grown even strongerOctober 3, 2024 | msn.comVoyageur Pharmaceuticals Ltd (VM)August 10, 2024 | investing.comUpdate - Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium ContrastMay 28, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?VM, LEAF, CRDL, and RX Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.52 +0.13 (+9.06%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$1.46 -0.06 (-3.96%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Leaf Group NYSE:LEAFLeaf Group Ltd., together with its subsidiaries, operates as a diversified consumer internet company worldwide. It operates in two segments, Marketplaces and Media. The Marketplaces segment offers Society6.com, which provides artists with an online commerce platform to feature and sell their original art and designs on consumer products in the wall art, home décor, and tech and apparel accessories categories. It also provides SaatchiArt.com and its related art fair event brand, which is an online art gallery where a global community of artists exhibit and sell their original artwork directly to consumers. The Media segment offers Well+Good, a health and wellness media brand that offers journalistic approach to content; and Livestrong.com, a destination and action-oriented community, as well as mobile applications, such as MyPlate that monitor users' health, fitness, and life achievements. This segment also provides Hunker, a home design media site for enabling first-time homeowners enhance their homes with practical solutions, home tours, and design advice for people; and Only In Your State, a US-focused local attractions and review site, which highlights small businesses, hidden gems, and natural wonders for the audience. In addition, this segment offers content creation, traffic source, mobile application, and monetization services; and develops partner sites. It sells its products through wholesale channels to trade and hospitality clients, as well as through retail distribution partners. The company was formerly known as Demand Media, Inc. and changed its name to Leaf Group Ltd. in November 2016. Leaf Group Ltd. was incorporated in 2006 and is headquartered in Santa Monica, California.BioSyent CVE:RXC$11.75 +0.05 (+0.43%) As of 07/3/2025 01:14 PM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Voyageur Pharmaceuticals CVE:VMC$0.30 -0.01 (-1.61%) As of 07/3/2025 03:59 PM EasternVoyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
